Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.

Jacobs Neurological Institute, Buffalo General Hospital, Buffalo, NY 14203, United States.
Journal of Neuroimmunology (Impact Factor: 2.79). 11/2008; 205(1-2):113-25. DOI: 10.1016/j.jneuroim.2008.09.004
Source: PubMed

ABSTRACT To characterize gene expression in multiple sclerosis (MS) patients after the first dose and chronic dosing of 30 microg, once weekly, intramuscular interferon-beta1a (IFN-beta) and to delineate the pharmacogenomic differences between Good Responders and Partial Responders to IFN-beta therapy.
The treatment responses after the first IFN-beta dose and chronic IFN-beta dosing were assessed in 22 relapsing MS patients (17 females, 5 males; average age: 41.5+/-SD 10.4 years). Gene expression profiles in peripheral blood mononuclear cells were obtained prior to treatment and at 1, 2, 4, 8, 24, 48, 120, 168 h after the first IFN-beta dose and at 1, 6 and 12 months after chronic dosing with once-weekly 30 microg IFN-beta-1a intramuscularly. Repeated measures statistics with false discovery rate control were used. The functional characteristics, biological pathways and transcription factor sites were analyzed.
Of the 1000 genes modulated following the first dose and upon chronic dosing of IFN-beta in MS patients, approximately 35% were up-regulated and 65% were down- regulated; the percentage of modulated genes in common was approximately 50%. The expression of the pharmacodynamic mRNA markers of IFN-beta effect showed differences in time profiles for the Good Responder and Partial Responders to IFN-beta therapy and the Jak-STAT, TNFRSF10B, IL6, TGFbeta, retinoic acid and CDC42 pathways were differentially modulated. The patients with side effects to therapy showed differences in the TGFbeta1, IFNG/STAT3 and TNF pathways.
Gene expression is a valuable tool for understanding the molecular mechanisms of IFN-beta action in MS patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The closed-cell aluminum foam processing by liquid melt method using titanium hydride (TiH2) decomposition method is studied for customizing the process variables for explicit requirements. Design of experiments (DOEs) is employed in this study, which is a technique for planning and conducting experiments and analyzing the responses to bring out valid and objective conclusions. In the first stage, four process variables such as, holding time, amount of TiH2, amount of calcium addition and stirring time after calcium addition were adopted to identify the most influencing process variables by using half-fractional factorial design. Holding time and the amount of TiH2 addition were recognized as the significant process variables and those parameters were studied for non-linear relationship at a higher-level design using response surface methodology (RSM). The developed empirical models were used to derive inferences on the influence of these process variables on foam structure like relative density, pore diameter and cell aspect ratio. These structural properties of the foam in turn govern the mechanical property of closed-cell aluminum foam and static compression tests were conducted to study the correlations between them.
    Materials Science and Engineering A-structural Materials Properties Microstructure and Processing - MATER SCI ENG A-STRUCT MATER. 01/2011; 528(4):2067-2075.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Systemic autoimmune diseases result from interactions between genes and environmental triggers that lead to dysregulation of both innate and adaptive immunity. Systems biology approaches enable the global characterization of complex systems at the DNA, RNA and protein levels. Recent technological breakthroughs such as deep sequencing or high-throughput proteomics are revealing novel inflammatory pathways involved in autoimmunity. Herein, we review recent developments, challenges and promising avenues in the use of systems approaches to understand human systemic autoimmune and autoinflammatory diseases.
    Current opinion in immunology 09/2013; · 10.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is characterized by episodes of inflammatory damage to myelin and oligodendrocytes in the central nervous system mediated by T, B, and Natural killer lymphocytes of various types, antibody and complement, dendritic cells, macrophages, microglia, and secreted cytokines and chemokines. These relapses cause significant neurologic dysfunction, which is only partially reversible, and eventual secondary progressive neurologic decline frequently occurs. Interferon-beta (IFNβ) has been a mainstay of MS treatment for more than 20 years after being proven to reduce relapse frequency and development of new lesions on magnetic resonance imaging. However, patient response is highly variable and the exact mechanisms of action are not fully understood. Breakthrough relapses and secondary progressive neurologic decline remain significant concerns in long-term MS treatment. Biomarkers may help elucidate the beneficial effects of IFNβ in MS and possibly guide therapeutic decision making given the variety of different therapies now available with varying mechanisms of action and risks. Various serum and cerebrospinal fluid candidate biomarkers have been described, but none have yet been proven to carry sufficient predictive reliability for routine clinical use.
    Journal of Interferon & Cytokine Research 08/2014; 34(8):600-4. · 3.90 Impact Factor